Blood cancer, enzymes & kidney cancer

[Guest guest]

Blocking enzyme could help in rare blood cancer.

http://www.caring4cancer.com/go/cancer/news?NewsItemId=20080917elin023.xml

Data backs benefits of new kidney cancer drug.

New clinical trial results endorse the long-lasting benefits of Novartis's new

kidney cancer drug Afinitor.

http://www.caring4cancer.com/go/cancer/news?NewsItemId=20080916elin028.xml

The findings suggest that popular new targeted therapies such as Novartis's

Gleevec may not work broadly, because they affect only one mutated gene, while

cancer is caused by dozens. It is extremely unlikely that drugs which target a

single gene like Gleevec will be active against a major fraction of solid

tumors.

http://www.caring4cancer.com/go/cml/news?NewsItemId=20080904elin017.xml

Leukemia patients may be able to avoid developing resistance to the drug Gleevec

through a mathematical formula that predicts when they should receive an

immune-boosting vaccine, researchers said on Thursday.

http://www.caring4cancer.com/go/cml/news?NewsItemId=20080620elin022.xml

Radich and colleagues have developed tests sensitive enough to detect one cancer

cell among a million normal cells, which allows doctors to evaluate initial

response to treatment or to swiftly initiate new therapy at the earliest sign of

relapse. DNA microarrays will determine the genetic changes that take place as

CML progress from its early chronic stage to later, more aggressive stages. The

work will improve patient outcomes by allowing doctors to tailor each patient's

treatment precisely to their disease stage. DNA microarrays to determine the

genetic changes that take place as CML progress from its early chronic stage to

later, more aggressive stages. The work will improve patient outcomes by

allowing doctors to tailor each patient's treatment precisely to their disease

stage.

By charting the sets of genes that are turned on or off as the disease

advances from early to more aggressive phases, scientists found reproducible

genetic " signatures " that could form the basis for tests to predict prognosis

and match patients with the best treatment for their illness. CML is a great

model disease for studying progression and devising a molecular clock.

http://www.fhcrc.org/research/diseases/cml/#highlight1

3/16/06

________________________________________________________

T. J. 's (Hutch cancer patient's) battle with leukemia video. Very

interesting video to watcch. An intimate look into the experience of a bone

marrow transplant recipient, from diagnosis to donor search, fundraising to

preparing for treatment, treatment to recovery.

http://www.fhcrc.org/patient/brandnewlife.html

Moving beyond cancer to wellness - suvivorship. Lance Armstrong Foundation.

http://tiny.cc/Ug8Xa

G'nite everyone and good reading,

Lottie